Start-up biotech companies should be focus of NIDA collaborative drug research, ad hoc group recommends.

BIOTECH START-UPS SHOULD BE FOCUS OF NIDA COLLABORATIONS, Morton Goldberg, University of Pennsylvania, said at a March 8 meeting of the National Institute on Drug Abuse extramural science advisory board in Rockville, Md. NIDA should concentrate on "ways to enhance industry involvement, focusing on start-up biotech companies," Goldberg said. He was reporting recommendations from an ad hoc panel of consultants that met March 7 to assess NIDA's drug development program.